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Abstract
Background: The use of oral systemic anticancer therapies (SACT) has increased and led to improved cancer
survival outcomes, particularly with the introduction of small molecule targeted agents and immunomodulators.
Oral targeted SACT are, however, associated with toxicities, which might result in reduced quality of life and non-
adherence. To reduce treatment-related toxicity, the practice of non-standard dosing is increasing; however guidance
to govern this practice is limited. A systematic review was conducted to identify evidence of, and outcomes from, non-
standard dosing of oral SACT in oncology and malignant haematology.
Methods: A comprehensive search of 78 oral SACT was conducted in the following databases: MEDLINE®, EMBASE®,
Cochrane Library©, and Cumulative Index to Nursing and Allied Health Literature (CINAHL©). Studies were selected
based on predefined inclusion/exclusion criteria, and were critically appraised. Extracted data were tabulated to summarise
key findings. Due to diversity of study designs and heterogeneity of reported outcomes, studies were categorised and
evidence was synthesised in three main themes: dose interruption; dose reduction; and other dosing strategies.
Results: Thirty-four studies were eligible for inclusion: four clinical trials, fifteen cohort studies and fifteen case reports.
Evidence for non-standard dosing was reported for eleven oral SACT. Dose interruptions were the most commonly
reported strategy (14 studies); nine studies reported dose reductions; and eleven reported other dosing strategies. Eight
retrospective cohort studies reported dose interruption of sunitinib in renal cell carcinoma and showed either similar or
improved responses and survival outcomes, and fewer or equivalent high grade toxicities, compared to the standard
schedule. Four cohort studies retrospectively evaluated dose reductions of imatinib, gefitinib or erlotinib, for chronic
myeloid leukaemia and non-small cell lung cancer, respectively. Other dosing strategies included alternate-day dosing. The
quality of the evidence was limited by the small sample size in many studies, retrospective study designs, and lack of
reported toxicity and/or QoL outcomes.
Conclusions: This review identified limited evidence to support current non-standard dosing strategies, but some of
findings, e.g. dose interruption of sunitinib, warrant further investigation in large-scale prospective clinical trials.
Keywords: Systemic anticancer therapy, SACT, Chemotherapy, Cytotoxic, Targeted therapy, Oral, Non-standard, Prescribing,
Dose, Review
Background
Systemic anticancer treatment (SACT) has undergone a
major revolution in the last decade [1]. The recent
discovery and approval of multiple oral SACT has led to
improved survival outcomes for people with cancer [1].
Oral SACT includes cytotoxic agents (e.g. temozolo-
mide), small molecule targeted agents (e.g. crizotinib),
immunomodulators (e.g. lenalidomide) and hormone
modulators (e.g. enzalutamide) [2], which have a variety
of molecular mechanisms and differing toxicity profiles.
Depending on the licensed dose, some agents are admi-
nistered daily and continuously until disease progression or
unacceptable toxicity, other agents are administered on
specific days with a scheduled break within the treatment
cycle, and some are administered for a specific treatment
duration then discontinued thereafter (e.g. temozolomide)
[2]. For instance, the licensed dose of imatinib for chronic
myeloid leukaemia (CML) in chronic phase is 400mg once
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daily continuously [3] and the licensed dose of sunitinib in
metastatic renal cell carcinoma (RCC) is 50mg once a day
for four consecutive weeks followed by a 2 weeks rest
period [4].
Many oral SACT are associated with high treatment
costs, particularly novel therapies. For instance in the
UK, the monthly National Healthcare Service (NHS)
indicative prices of sunitinib 50 mg capsules, imatinib
400 mg tablets, and lenalidomide 25 mg capsules, ac-
cording to the British National Formulary (BNF) are
£3138.80, £1946.67 and £4368.00, respectively [2] and
the monthly cost of combination therapy for meta-
static melanoma (dabrafenib/trametinib) at full dose is
£10,400 [2].
Oral SACT are associated with high-grade toxicities
that lead to dose reduction, dose interruption/delay, or
treatment discontinuation [5]. High-grade toxicities can
reduce quality of life (QoL), and subsequent dose inter-
ruption or treatment discontinuation may reduce treat-
ment efficacy [5–7]. One approach to maintain patients
on continuous SACT is to prescribe non-standard doses,
where unlicensed doses/schedules are used to reduce
toxicities, improve quality of life (QoL) and extend the
duration of therapy.
Governance guidelines are implemented nationally
and locally in the UK to ensure evidence-based safe
and effective prescribing practice, which is based on
robust evidence from large clinical studies and is
undertaken in accordance with the Summary of Pro-
duct Characteristics (SPC) [8]. In the UK, the
National Institute for Health and Care Excellence
(NICE) assesses evidence to produce up-to-date rigor-
ous guidelines and recommendations on indication,
licensing, approvals, and dosing of all oral SACT [9].
Guidance governing non-standard oral SACT doses is,
however, either limited or non-existent.
An initial scoping review about non-standard dosing
strategies of oral SACT did not identify any published
comprehensive reviews on this topic. Yet, case reports
and cohort studies investigating these strategies have
been published: Dooley et al (2014) reported a case
series of 6 melanoma patients managed with dose reduc-
tions and/or intermittent dosing of vemurafenib [10];
Popat et al (2014) reported a retrospective cohort study
of 39 myeloma patients treated with alternate day dosing
of lenalidomide [11].
The purpose of this systematic review was, there-
fore, to identify evidence of, and outcomes (efficacy,
toxicity, QoL) from, non-standard dosing of oral
SACT in oncology and malignant haematology, in
order to inform prescribing practices. A secondary
aim of this review was to inform future research that
aims to evaluate the feasibility of oral SACT
non-standard dosing practice.
Method
Search strategy
The review was conducted following systematic review
criteria described by Grant and colleagues (2009) and in
accordance with the Preferred Reporting Items for Sys-
tematic Review and Meta-Analysis Protocols (PRISMA-P)
guidelines [12, 13]. The review protocol was registered on
the PROSPERO database (CRD42017076195) and pub-
lished prior to conducting the review [14]. The protocol
paper details the full search strategy [14].
Search terms used were drug names of 78 (all) oral
SACT listed in the British National Formulary (2017)
[2], relevant Medical Subject Headings (MESH) terms
for anticancer agents, and synonyms for non-standard
dosing [14]. The list of oral SACT included in the search
strategy is presented in Additional file 1: Table S1. The
search terms were used with the Boolean operators
AND and OR to search MEDLINE®, Embase®, Cochrane
Library©, and Cumulative Index to Nursing and Allied
Health Literature (CINAHL©) databases [14]. No date
restriction was applied, but the search was restricted to
English language. The search was completed in September
2017 and was updated in April 2018. The search was ex-
panded using prospective citation chaining in the Web of
Science and retrospective snowballing of reference lists of
included studies to ensure a sensitive, comprehensive
search.
Screening search results
Search results were independently double-screened by
the research team using eligibility and exclusion criteria
shown in Table 1, both at abstract and full text screening
Table 1 eligibility criteria
Eligibility Criteria
Inclusion Exclusion
•Studies of malignant disease
•Studies of patients aged ≥18
years
•Studies of oral SACT with
non-conventional dosing
•Studies examining the
prescribing practices using
unlicensed (non-standard)
doses or schedules of oral
SACT
•Meta-analysis
•Late phase clinical trials
•Cohort studies
•Cross-sectional studies
•Retrospective studies
•Observational studies
•Case-control studies
•Case-reports
•MHRA: reports, legislative
documents
•Studies of parenteral SACT
(e.g. IM, IV, SC, IT)
•Studies of oral SACT where
non-conventional dosing has
been used, but cannot be
extracted independently of
other reported data
•Studies comparing different
licensed doses of oral SACT
for the same antineoplastic
indication
•New standard dose-finding
studies
•Animal studies
•Early phase clinical trials
•Pharmacokinetic studies
•Narrative reviews
•Opinion papers
•Education papers
•Commentaries
•Editorials
•Conference abstracts
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stages. Disagreements between two researchers were
reviewed by a third researcher to reach agreement.
Quality appraisal and data extraction
Standardised Critical Appraisal Skills Programme
(CASP) tools were used to appraise the quality of study
design and reporting [15]. CASP tools used were specific
for the type of study reviewed (e.g. randomised clinical
trial, cohort study, and case report) [15]. Studies were
assigned a quality rating of high, moderate to high, mod-
erate, moderate to low, or low. Decisions were made to
include lower quality studies where relevant data had
been reported; limitations of data reported in lower
quality studies was transparently reported in the review.
Extracted data were tabulated using pre-defined catego-
ries in order to sort and analyse key findings (Table 2).
Data extraction
Extracted data was reviewed by all the research team
and tabulated to effectively report key findings. Key data
extracted from each study were: author and year of pub-
lication, aims, design, drug schedule, and reported out-
comes (efficacy, toxicity and QoL) (Table 2).
Data analysis
In view of diversity of study designs, variability in num-
bers of identified studies per drug, and heterogeneity in
reported outcomes from one study to another, studies
were categorised into the themes: dose interruption;
dose reduction; and other dosing strategies. The research
design and characteristics of non-standard dose inter-
ventions, clarity of reporting, and statistical significance
of reported data, were assessed to determine the
strengths and limitations of the evidence base as a whole
under each of the above themes. The findings of this
analysis are presented below.
Results
Search results
Of 5486 search results, 31 studies were eligible for inclu-
sion. One study was later excluded because treatment
schedules used were not in line with current practice [16].
During the process of search expansion, four additional
studies were included [10, 17–19]. In total, 34 studies met
eligibility criteria for this review (Fig. 1); 23 reporting
non-standard dosing of oral SACT in solid tumours and 11
in haematological malignancies. Four studies were late
phase clinical trials [20–23], 15 were cohort studies and 15
were case reports. Non-standard dosing was identified for
eleven different oral SACT, as reported in Tables 3-5. The
number of studies per drug investigated was as follows:
sunitinib (10), imatinib (7), sorafenib (2), vemurafenib (3),
dasatinib (2), lenalidomide (2), crizotinib (2), erlotinib (2),
gefitinib (2), temozolomide (1) and thalidomide (1). Nine
studies were conducted in Italy, eight in Japan, 6 in the
USA, three in the UK, three in Germany, two in South
Korea, one in each of Brazil, China and Austria.
Non-standard dosing strategies reported were dose inter-
ruptions, dose reductions and a variety of other strategies.
Dose interruption strategies were the most common
non-standard dosing strategy described (14 studies), dose
reductions (9 papers), and other dosing strategies (11
studies, of which, two reported the use of alternate day
dosing of lenalidomide [11, 23]).
Quality appraisal
For dose interruption studies, clinical trials were appraised
as moderate to high [21, 22], moderate [23] and moderate
to low [20]. Cohort studies were moderate to high [24],
moderate [25–27] and moderate to low [28–31]. Case
reports were moderate [10, 32].
For dose reduction studies, cohort studies were ap-
praised as moderate [18, 33] and moderate to low [34, 35].
The quality of case reports was moderate [17], moderate
to low [19, 36, 37] and low [38].
For the remaining various dosing strategies, cohort
studies were appraised as moderate [11, 39], and mode-
rate to low [40]. Case reports were moderate [41–43]
and moderate to low [44–48].
Non-standard dosing strategies
Dose interruptions
Three clinical trials reported findings from non-standard
dose interruptions (Table 3). A small randomised trial
Table 2 Data extraction table
Data to be extracted Item
Publication ID • Author
• Publication date
Study aim • Title/Purpose/Aim
Study design • Study type: meta-analysis, late
phase clinical trial, cohort study,
cross-sectional study, retrospective
study, observational study,
Case-control study, case-report
• Measurement tools, instruments,
measures, outcome criteria
Non-conventional
dosing characteristics
• Oral SACT name
• Dose
• Duration of therapy
Sample characteristics • Number of participants
• Country
• Age
• Gender
• Cancer type
Findings • Reported efficacy outcomes
• Reported side effects/toxicity outcomes
• Reported health-related quality of life
• Any other findings
Strengths and limitations • Findings of critical appraisal
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(n = 23) conducted by Mangiacavalli and colleagues
(2012) investigated efficacy and adverse effects of a
one-week interruption of thalidomide following daily ad-
ministration for 3 weeks, compared to continuous ther-
apy [21]. The study reported a trend for worse overall
survival (OS, p < 0.001) and progression free survival
(PFS, p = 0.02) in the intermittent arm compared to the
continuous arm, with no difference in peripheral neu-
ropathy; however patient numbers in this study were
very small (≤ n = 30), which prevented this trial from
obtaining definitive efficacy data [21]. Mangiacavalli and
colleagues (2012) highlighted the place of this dosing
strategy in patients experiencing toxicity (peripheral
neuropathy), but recommended that a balance needs to
be maintained with the desired efficacy outcomes [21].
Dose interruption was also not supported by findings
from a single-arm, non-randomised recurrent glioma
trial (n = 90, of which n = 64 had glioblastoma) [20]. The
standard cycle 1 dose of temozolomide monotherapy for
the treatment of glioma is 150 mg/m2 once a day for 5
days (days 1-5) of every 28 days cycle [2]. This trial in-
vestigated an alternative schedule (days 1-7, and days
15-21 of a 28 days cycle, i.e. 1-week-on/ 1-week-off ) [20].
PFS rate in glioblastoma group was 43.8% at 6 months,
median PFS was 24 weeks [20]. OS rate at 12 months
was 23%, median OS was 38 weeks [20]. Toxicity out-
comes were reported, but QoL outcomes were not [20].
Data from this trial suggest that the alternating weekly
schedule of temozolomide showed clinically meaningful
improvement in survival outcomes compared to the
registration trial (PFS rate at 6 months: 21%) [20]. Wick
and colleagues (2007) argued that the alternating-weekly
schedule is feasible, safe, and effective and recom-
mended further investigation of this strategy in rando-
mised studies [20].
Russo and colleagues (2015) conducted a single arm,
open-label trial, in which they investigated the use of 1
month on/1 month off schedule of imatinib in 96 CML
patients aged ≥65 years [23]. Although this trial did not
report toxicity or QoL outcomes, there were no
Fig. 1 Flow diagram of search strategy and inclusion/exclusion
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transformations (progressions) of CML to an accelerated
or blast phase of disease using this alternative schedule
[23]. However, 16 patients lost complete cytogenetic
response (CCgR) and molecular response (MR3.0) and
16 patients lost MR3.0 alone [23]. In optimal and stable
responders, Russo and colleagues (2015) suggest that be-
cause all the patients who relapsed could be brought
back to optimal response, a policy of intermittent
imatinib treatment is feasible, successful in about 50% of
patients, and safe [23].
Dose interruption strategies were also reported in one
clinical trial and eight retrospective cohort studies, which
investigated the use of non-standard schedules of sunitinib
in renal cell carcinoma (RCC) (Table 3). Jonasch and col-
leagues (2018) conducted a small (n = 59) phase II single
arm open label study of sunitinib in previously untreated
RCC [22]. Patients were started on 50mg 2 weeks on and
1 week off, and were eligible for further dose/schedule re-
ductions (Level − 1 to − 5) [22]. The primary endpoint was
< 15% ≥G3 fatigue, diarrhoea or hand-foot syndrome
(HFS) [22]. The latter was not met because 25% experi-
enced one of those ≥G3 toxicities [22]. Jonasch and
colleagues (2018) described how their primary end point
of decreased grade 3 toxicity was not met; however treat-
ment with this modified schedule is associated with
reduced grade 4 toxicity, a low patient discontinuation
rate, and high efficacy [22].
Most of the sunitinib cohort studies compared standard
dosing of (4 weeks on and 2 weeks off), to (2 weeks on
and 1 week off), except for one study, which did not detail
the non-standard dose and schedule (reported as any
dosing schedule different to standard) [29]. Due to
variance in reported outcomes in these cohort studies, it
was not possible to conduct meta-analysis on this data;
however key findings are summarised as follows.
The sample size of sunitinib cohort studies ranged
widely from 8 to 460 participants (mean = 150). Reported
efficacy outcomes included, complete response (CR),
partial response (PR), overall response rate (ORR), OS,
PFS; in addition to toxicity. QoL outcomes were only
reported in two studies. Where reported, participants
receiving alternative dose interruption schedules showed
either similar or improved responses and survival out-
comes, and fewer or equivalent high grade toxicities, com-
pared to standard schedule. Overall, authors of the eight
retrospective studies recommend that intermittent dosing
should be further investigated in prospective studies to
confirm its safety and efficacy.
Vemurafenib dose interruption was reported in two
case reports [10, 32]. One report of one case described a
number of dosing levels employed [32], and the other
case report described dosing levels variable from one
patient to another (n = 6), and a range of reponses (from
good to disease relapse) [10]. Dooley and colleagues
(2014) recommend that in clinical practice, intermittent
dosing should be considered as an alternative to dose re-
duction/termination in the management of vemurafenib
toxicity [10].
Dose reductions
Four cohort studies retrospectively evaluated dose reduc-
tions of either imatinib to treat CML, gefitinib or erlotinib
to treat NSCLC [18, 33–35]. Clinical efficacy outcomes
were reported as one or more of the following: time to pro-
gression (TTP), PFS OS, in addition to toxicities. QoL was
not reported for any of the cohorts. None of these studies
reported all outcomes (i.e. efficacy, toxicity, and QoL).
Breccia and colleagues (2010) reported findings that
could not be easily interpreted for the purpose of this re-
view, because OS was not compared between the different
imatinib doses used [18]. In addition, Jung Sung and
colleagues (2014) did not report sufficient detail about ima-
tinib dose reductions received to be able to fully analyse
findings in this review [33]. Neither imatinib study refer-
enced above reported QoL or sufficient toxicity outcomes
(i.e. none reported by Breccia et al., and only toxicities lead-
ing to dose reductions reported by Jung Sung et al). Breccia
and colleagues (2010) recommend that longer follow-up
and further observation of a larger cohort of CML patients
are required to establish the safety and the long-term re-
sponses to dose reduction of imatinib [18]. From their find-
ings, Jung Sung and colleagues (2014) suggest that imatinib
dose adjustments that take into account body surface area
(BSA), could improve the clinical outcomes in patients with
chronic phase CML [33]; but like other authors of studies
reviewed herein, recommend that further prospective
studies are required [33].
A large cohort study comparing standard dose (n = 240)
to dose-reduced (n = 23) gefitinib showed improved
median OS and PFS in the dose-reduced subgroup [35].
The study only reported toxicities leading to dose reduc-
tions. Similarly, Binder and colleagues (2010) compared
standard dose of erlotinib (n = 31) to two dose reduction
groups (n = 9; n = 9) in patients with NSCLC and reported
TTP, but no survival outcomes [34]. Patient numbers were
unequal between the standard dose subgroup and dose re-
duction subgroups. Although, Hoon Sim and colleagues
(2014) recommend further investigation of dose reduction
of gefitinib in a prospective trial [35], Binder and col-
leagues (2010) did not report a clear recommendation for
or against erlotinib dose reduction for the treatment of
NSCLC [34].
Dose reduction strategies were also reported in five case
studies (Table 4) that described the use of reduced doses
of imatinib or dasatinib for CML [17, 19, 37], and sorafe-
nib for advanced hepatocellular cancer (HCC) [36, 38].
Serpa and colleagues (2010) and Jamison and colleagues
(2016) suggested that low-dose dasatinib therapy in
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intolerant patients may be tried before drug discontinu-
ation [17, 37] or a change is considered [37]. In addition,
Zipin and colleagues (2014) recommended to conduct a
dose reduction trial in this patient cohort [19]. Shinoda
and colleagues (2015) recommended that sorafenib dose
reduction described in their report should be further
explored [36].
Other dosing strategies
Three cohort studies investigated other dosing strategies
including alternate-day dosing of gefitinib for NSCLC
[39], lenalidomide for myelodysplastic syndrome (MDS)
and multiple myeloma (MM) [11, 40] (Table 5).
Lenalidomide studies were single arm cohorts, al-
though the MM study was prospective [11]. All three
studies had small sample sizes. Alternate dosing of gefi-
tinib was found to have non-inferiority in response and
disease control rates compared to standard [39]. Toxicity
outcomes were only reported in the MM study. QoL
were not reported for any of the three studies. Authors
of the two alternate dosing of lenalidomide recommend
either for this schedule to be explored in a larger cohort
of patients [40], or for its clinical outcomes to be con-
firmed in prospective studies [11]. Satoh and colleagues
(2011) identify the specific needs to test non-standard
gefitinib dosing schedules in frail patients who are at risk
of treatment toxicity [39].
Eight case studies reported a variety of alternative dos-
ing strategies (Table 5). These small studies described
non-standard dosing practices in patients receiving
either imatinib for leukaemia or gastrointestinal stromal
tumour (GIST) [41, 44, 48], crizotinib or eroltinib for
NSCLC [42, 46, 47], vemurafenib for malignant
melanoma [45], and sunitinib for RCC [43]. Some of the
evaluated strategies included combinations of intermit-
tent dosing, and various dose reductions in response to
experienced toxicities. For example, Faber and colleagues
(2006) used imatinib in CML at doses ranging from to
300 mg to 600 mg, and frequencies ranging from one to
five times a week in 12 patients, rather than a daily dose.
This was considered a plausible treatment option for pa-
tients with persistent myelotoxicity [41] Other authors add-
itionally suggested that non-standard dosing strategies may
help to individualise treatment to reduce toxicities [46, 47],
maintain QoL and support patient compliance [43].
Discussion
This review aimed to systematically identify evidence of, and
outcomes (efficacy, toxicity, QoL) from, non-standard dos-
ing of oral SACT in oncology and malignant haematology,
in order to inform prescribing practices. This review identi-
fied a wide range of study types: clinical trials, prospective
and retrospective cohort studies as well case reports/series.
Included studies ranged across both solid tumours (two
thirds of all included studies) and malignant haematology
(one third). The amount and quality of reported outcomes
depended considerably on the study design. Efficacy/survival
outcomes were reported in most studies. Varying toxicity
outcomes were reported in cohort studies and case reports.
QoL outcomes were not reported in the majority of studies.
In order to inform current prescribing practice, this review
focused on categorising common non-standard dosing
interventions. The secondary aim of this review, which was
to inform research evaluating the feasibility of oral SACT
non- standard dosing practice, has been partially met by in-
dicating some non-standard dosing strategies that warrant
further investigation in large-scale randomised controlled
trials.
Our recommendations for non-standard dosing
strategies based on the evidence reviewed herein are
as follows:
Drug interruption strategy
The benefit of dose interruption was dependent on the
individual drug, with some studies showing no benefit.
Although data reported in the temozolomide single arm
non-randomised trial does not provide statistically sig-
nificant evidence to implement its dose interruption
strategy [20], the intervention does warrant further in-
vestigation in a large randomised controlled trial. This
recommendation is in line with recommendations of
study authors.
Results from the imatinib (1 month on/off ) trial do
not draw definitive conclusions that intermittent treat-
ment can be offered to optimal and stable responders
[23]. The findings, however, indicate a role for alterna-
tive treatment schedules tailored to individual patients,
particularly those experiencing significant toxicities, in
agreement with study authors.
Drawbacks of the sunitinib dose interruption trial in
RCC were small patient number, single arm design, and
lack of detailed reporting of PFS, OS and toxicities out-
comes for levels − 1 to − 5 dose reductions [22]. QoL
outcomes were not reported [22]. In addition, the trial
did not meet its primary endpoint of < 15% ≥G3 toxic-
ities using alternative schedule but equally it did not
compare this schedule to standard dosing schedule
[22].Therefore, this small phase II trial does not provide
sufficient evidence to issue a generalised recommenda-
tion to employ sunitinib dosed at 50 mg 2 weeks on and
1 week off, as alternative to standard dose. A larger scale
randomised prospective study which compares this do-
sing strategy of sunitinib to its traditional dosing sche-
dule is warranted in order to draw conclusions.
Evidence from the cohort studies that examined the
use of dose-interrupted sunitinib for patients with RCC
did suggest some benefit over standard dosing, so it
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might be considered as a strategy for reducing toxicity
in patients prescribed sunitinib for RCC. In the absence
of robust efficacy/toxicity/QoL outcomes data, however,
evidence from these cohort studies is not sufficient to
support the described sunitinib dosing schedules as al-
ternative to standard dosing. We agree with the overall
recommendation of others that this strategy warrants
further investigation in a large prospective clinical trial
to ensure efficacy, safety and improved patient-reported
outcomes.
Although Dooley and colleagues (2014) recommended
that in clinical practice intermittent dosing should be
considered as an alternative to dose reduction/termin-
ation in the management of vemurafenib toxicity, we did
not find sufficient evidence to issue a generalised recom-
mendation to employ dose interruptions of vemurafenib
in melanoma, based on the two case reports identified in
this review [10, 32].
Dose reduction strategy
The four cohort studies that retrospectively evaluated
dose reductions of either imatinib to treat CML, gefitinib
or erlotinib to treat NSCLC [18, 33–35] have a number
of limitations, such as retrospective design, unequal
patient numbers, and lack of reporting of toxicity and/or
QoL outcomes. In agreement with authors of these co-
hort studies, it was not possible to draw conclusions
about the impact of dose reduction based on the evi-
dence reviewed in the above four cohort studies.
Out of the five case studies (Table 4) that described the
use of reduced doses of imatinib or dasatinib for CML
[17, 19, 37], and sorafenib for advanced hepatocellular
cancer (HCC) [36, 38], very few studies reported toxicity
or QoL outcomes. Although Serpa and colleagues (2010)
and Jamison and colleagues (2016) suggested low-dose
dasatinib therapy before treatment discontinuation due to
toxicity [17, 37], based on efficacy and survival outcomes
alone, we did not find sufficient evidence to support such
dose reductions.
Other dosing strategies
Evidence from the three cohort studies identified this
review is not sufficient to support alternate day dosing
of gefitinib or lenalidomide [11, 39, 40], but it calls for
investigation in large scale randomised prospective clin-
ical trials to compare it to standard dosing, in agreement
with study authors. Alternate day dosing of lenalidomide
is emerging in practice as a non-standard dosing strat-
egy. However, there is currently no evidence from
robust, randomised, large-scale studies assessing the effi-
cacy, safety and QoL outcomes to support this practice
routinely.
Overall, results from the case reports were inconclu-
sive, primarily due to limitations in the design of the
studies, small sample sizes and lack of detail in reporting
toxicities and QoL outcomes. Our findings, therefore,
differ from some case studies authors who suggest that
modified schedules for imatinib, crizotinib and sunitinib
can be used to manage toxicities.
In the UK, in view of the increasing cancer popula-
tion and new available therapies, prescribing practice
undertaken by physicians has been extended to
non-medical prescribers (NMP) in the healthcare
workforce to meet capacity demands. All prescribers
in cancer clinics, including NMPs, need clear proto-
cols, guidelines, and algorithms to support clinical de-
cisions about safe, effective and in-context prescribing
practice. Findings from this review are a reflection of
increasing current practice of non-standard dosing of
oral SACT.
Prescribers meet recurrent challenges of maintaining
patients on life-saving cancer treatments, which carry
varying risks from a wide spectrum of limiting toxicities.
Intentional non-adherence and patient-controlled dosing
(i.e. taking the drug only when patient feels able to) due
to treatment toxicity has been reported and can result in
diminished extent of clinical benefit from therapy [49],
and sub-optimal prospects of the overall treatment path-
way. It is, therefore, imperative that clinical trials take
into account real-life, intention to treat data when ana-
lysing the efficacy of licenced drugs, so that protocols
and guidelines support safe and efficacious practice.
Supportive care, depending on toxicity of a specific
drug, is used to treat acute toxicities e.g. topical products
to prevent or treat cutaneous toxicity from erlotinib [50]
or to speed up recovery e.g. use of granulocyte-colony
stimulating factor in patients treated with lenalidomide to
stimulate neutrophil production [51]. In addition, for first
generation oral SACT (e.g. imatinib), physicians tend to
use their clinical judgment based on experience of pre-
scribing the drug to apply alternative dosing schedules to
manage toxicities and maintain a disease response on an
individual basis.
For newer generation oral SACTs, adjusting the dose
of oral SACT to manage toxicities usually follows
recommendations from the Summary of Product
Characteristics (SPC), but depends on the practice of the
individual prescriber. Strategies can include dose-
interruption until toxicity reduces or totally resolves,
dose-reduction or in cases with high-grade toxicity
treatment discontinuation. In the case of the UK,
funding for novel agents by NHS England (NHSE) is
in place where prescribing follows evidence, NICE
recommendations and Cancer Drugs Fund (CDF) cri-
teria [52]. Use of unlicensed oral SACT dosing stra-
tegies is, therefore, not funded.
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The number of licensed oral SACT evaluated in this
review was 78 [2]. Licensing of newer agents, such as
new oral kinase inhibitors and T-cell checkpoint inhibi-
tor immunotherapy, will inevitably change the way
some cancers, such as renal cell carcinoma, are cur-
rently treated. It is important, however, to acknowledge
the likelihood of both the ongoing use of current oral
SACT and an increase in non-standard dosing
strategies to manage toxicities, improve QoL, and ul-
timately maintain patients taking these agents in the
longer-term.
This review reports findings from studies that describe
and evaluate alternative prescribing strategies for suniti-
nib. These strategies suggest a role for dose-interruption
strategies using this drug to treat RCC, but large rando-
mised controlled trials are needed to determine statisti-
cally significant, clinically meaningful results about
treatment responses (OS and PFS), toxicities and QoL.
Studies are also needed to explore how non-standard
dosing of oral SCT, such as dose interruption, might
affect treatment adherence.
Dose-reduced imatinib in CML can be explored as an
option particularly in older patients with major cytogen-
etic or molecular responses. Dose reductions of other
agents such as gefitinib, crizotinib and sorafenib are not
supported by findings of this review. Prescribers might
choose to use dose reduction for individual patients to
support continuation of treatment prior to cessation due
to toxicities, as reported in the imatinib in CML trial
and sunitinib in RCC cohort studies.
Due to the very high cost of oral SACT, future
non-standard dosing studies should include health eco-
nomics and utility analysis. Use of dose interruptions or
dose-reduction suggests a cost-saving, because fewer
doses are prescribed and administered, and reduced
costs can result from these toxicity management stra-
tegies. This does, however, need to be balanced with the
potential outcome to treatment, and the need for an evi-
dence base for these alternative strategies to confirm
their efficacy, toxicity and QoL profiles.
Strengths and limitations
No previous systematic review has explored the prac-
tice of non-standard dosing of oral SACT. To ensure
transparency and to facilitate scrutiny of this review,
a systematic protocol was registered and published
prior to conducting the review, which was undertaken
according to best practice and reporting guidelines.
Each stage of the review process was independently
double-screened and any discrepancies discussed
among the research team until agreement was
reached. There was no date limitation imposed on the
review, so studies were selected on the basis of pre-
scribing practices that were relevant to current
practice. One limitation of the search strategy was
restricting the search to publications in English; how-
ever the search expansion strategy ensured a compre-
hensive and sensitive review.
One of the challenges of this study was reviewing evi-
dence generated from a diverse range of study designs
and variety of tumour-types treated with different oral
SACTs. Although this constrained the ability to conduct
a meta-analysis, retrieving a breadth of literature was
deemed necessary to fully scope non-standard dosing
practices in the treatment of oncological and haemato-
logical tumours. We chose to analyse findings of the re-
view by type of non-standard prescribing strategy, due
to the limited number of studies published about any
one drug, with the exception of sunitinib. It is possible
that analysing the data from any single drug used for a
specific tumour type might provide more robust recom-
mendations; however we would argue that currently the
data set is not sufficiently large to conduct this type of
analysis, which is a limitation of this review.
The quality of evidence reviewed was limited by the
small sample size of many studies, baseline characteris-
tics not being reported or recorded, use of retrospective
study designs, lack of measurement of toxicity and/or
QoL outcomes, and some dose-reduction studies not
reporting the reduced dose administered. Studies were
also un-blinded, which possibly could have been blinded.
Lack of baseline measurements meant it was difficult
to assess whether there was any bias due to multiple var-
iables between treatment groups. There was also lack of
detail in reporting toxicity outcomes in some studies.
Given the justification for using non-standard dosing is
to alleviate toxicity, we consider that fully measuring
toxicity and quality of life outcomes is a fundamental re-
quirement when investigating non-standard dosing strat-
egies. There was also an absence of health economics
and utility analysis, except for one study [11].
Conclusions
There is limited evidence to support current non-standard
prescribing practices. There is an indication that dose
interruption might be a safe and efficacious strategy to re-
duce treatment toxicity for patients prescribed sunitinib
for RCC. This strategy might also have a role in other
tumour groups and other types of oral SACT; however
there is a need for large-scale, ideally blinded, prospective,
RCTs that measure OS, PFS, toxicity outcomes, QoL out-
comes and health utilities to be conducted.
Additional file
Additional file 1: Table S1. List of oral SACT included in the search
strategy. (DOCX 16 kb)
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